(Q33156379)

English

Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

22 July 2017

Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial (English)

1 reference

Europe PubMed Central

22 July 2017

arterial hypertension

1 reference

based on heuristic

inferred from title

object named as

P Jansa

4

0 references

author name string

N Galiè

1

1 reference

Europe PubMed Central

22 July 2017

Lj Rubin

2

1 reference

Europe PubMed Central

22 July 2017

Mm Hoeper

3

1 reference

Europe PubMed Central

22 July 2017

H Al-Hiti

5

1 reference

Europe PubMed Central

22 July 2017

Gmb Meyer

6

1 reference

Europe PubMed Central

22 July 2017

E Chiossi

7

1 reference

Europe PubMed Central

22 July 2017

A Kusic-Pajic

8

1 reference

Europe PubMed Central

22 July 2017

G Simonneau

9

1 reference

Europe PubMed Central

22 July 2017

language of work or name

0 references

publication date

1 June 2008

1 reference

Europe PubMed Central

22 July 2017

1 reference

Europe PubMed Central

22 July 2017

371

1 reference

Europe PubMed Central

22 July 2017

9630

1 reference

Europe PubMed Central

22 July 2017

2093-2100

1 reference

Europe PubMed Central

22 July 2017

Primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960919-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The endothelin system in pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960919-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Pulmonary Arterial Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960919-8

7 January 2021

based on heuristic

inferred from DOI database lookup

ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960919-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960919-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Bosentan therapy for pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960919-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960919-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960919-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960919-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960919-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960919-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960919-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960919-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960919-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhaled iloprost for severe pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960919-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Beraprost therapy for pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960919-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Sitaxsentan therapy for pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960919-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960919-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Sildenafil citrate therapy for pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960919-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960919-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960919-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960919-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960919-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Reference equations for the six-minute walk in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960919-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of European post-marketing surveillance of bosentan in pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960919-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960919-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960919-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960919-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960919-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960919-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(08)60919-8

1 reference

Europe PubMed Central

22 July 2017

release_zxh2o5j3o5fklc7dqb2nf3yoe4

1 reference

https://api.fatcat.wiki/v0/release/zxh2o5j3o5fklc7dqb2nf3yoe4

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

22 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33156379&oldid=1843861954"